This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2004-2016.
Company Filing History:
Years Active: 2004-2016
Title: Igor Belyakov: Innovator in Immunology
Introduction
Igor Belyakov is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 2 patents, Belyakov's work focuses on enhancing immune responses and developing methods for treating infections.
Latest Patents
Belyakov's latest patents include "Immunostimulatory combinations of TLR ligands and methods of use." This invention provides immunostimulatory combinations of TLR ligands and therapeutic methods that involve administering these combinations to a subject. The described combinations can elicit an increased immune response compared to other existing immunostimulatory combinations. Another notable patent is "Mucosal cytotoxic T lymphocyte responses," which outlines methods for inducing an antigen-specific, mucosal cytotoxic T lymphocyte response. This response is useful in preventing and treating infections caused by pathogens that enter through mucosal surfaces.
Career Highlights
Igor Belyakov is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research in immunology and contribute to advancements in therapeutic methods.
Collaborations
Belyakov has collaborated with notable colleagues, including Jay A Berzofsky and Michael A Derby. These collaborations have further enriched his research and innovation in the field.
Conclusion
Igor Belyakov's contributions to immunology through his patents and research at the National Institutes of Health highlight his role as a key innovator in the field. His work continues to pave the way for advancements in immune response therapies.